TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cytomegalovirus
Recent findings from Chimerix, Inc. highlight research in cytomegalovirus
January 13th, 2009
"CMX001 is a lipid (1-O-hexadecyloxypropyl) conjugate of the phosphonate nucleotide analogue cidofovir (CDV). CDV, which is approved by the FDA for the treatment of cytomegalovirus (CMV)-induced retinitis in AIDS patients, is active against all five families of double-stranded DNA (dsDNA) viruses that cause human morbidity and mortality," investigators in the United States report. "However, the clinical utility of the drug is limited by the need for administration by intravenous infusion and the possibility of acute nephrotoxicity. The formation of the lipid conjugate increases in vitro antiviral activity up to a thousandfold, promotes high oral bioavailability and...
Source: TB & Outbreaks Week (2009-01-13)
|
